Blue Membranes Closes a License, Manufacturing and Supply Agreement with Goodman
News Apr 11, 2006
Blue Membranes has licensed out its proprietary drug-delivery coating technology to Goodman and Avantec for the development and global marketing of a drug-eluting stent based on pimecrolimus and other drugs.
The Blue Membranes technology enables Goodman to get access to the advanced drug-delivery technology based on inorganic nano-composites for combinatorial devices.
This agreement allows Goodman to exploit the current and future combinatorial device portfolio in the coronary stent sector and focus on all global markets.
Sohil Asgari, CEO and CTO of Blue Membranes commented, "The agreement is a very important step for Blue Membranes for establishing its disruptive technology in the strategic markets of the US and Japan."
"We will see more and more evidence being available in the public domain about the superiority of the Blue Membranes technology in terms of bio-inertness, deliverability of drugs, functionality and compatibility with new devices like ultra-thin strut, bifurcation or peripheral stents."
"We will reach the point very soon where one can not withhold this breakthrough technology for improving clinical outcomes to patients."
Furthermore, he pointed out that Blue Membranes has developed a library of 10,000 different material combinations for porous inorganic drug-delivery coatings also allowing multi-functional coatings with MRI shielding, x-ray labelling and other additional benefits.
Akira Yamamoto, President of Goodman, explains, "I believe Blue Membranes' innovative technology combined with Goodman's proven product designs will give us a head start in the race to market for a new generation of drug eluting stents (DES)."
"This polymer-free coating combined with our stent's excellent clinical results will make our DES a leader in nextgeneration drug eluting stents."
Blue Membranes has closed a license and supply agreement with the India based leading medical device manufacturer Relisys Medical Devices in May 2005.
This collaboration resulted in the development of a paclitaxel-eluting cobalt chromium coronary stent with a carbon-based nano-composite coating that is currently in the stage of clinical trials.
A new experimental system has been designed that can rapidly assess the pathogenic effects of a drug on a baby's developing brain. The system uses embryonic stem cells reprogrammed into neurons, and offers a powerful tool for probing genetic and molecular underpinnings of drug-induced neurodevelopmental disorders.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE